MMS Holdings, Inc.
United States
40 articles about MMS Holdings, Inc.
-
MMS Announces Key Executive Appointment to Support Company's Next Stage of Growth
8/30/2022
MMS Holdings Inc. – a leading contract research organization – announced the appointment of Kelly J. Hill to Chief Strategy Officer.
-
MMS Academy Launches Mobile App for Accessing Pharmaceutical Industry Virtual Learning Courses From Anywhere
10/28/2020
MMS Holdings – an award-winning, data-focused CRO – announced that its learning arm, MMS Academy, now offers access to all of its virtual pharmaceutical industry courses through a mobile smart device application.
-
MMS Academy Partners With MPGI to Bring Pharmaceutical Industry Virtual Learning to Students Across India
8/18/2020
MMS Holdings Inc. announced that Maharana Pratap Group of Institutions has partnered with MMS Academy, the learning arm of MMS.
-
Green Valley Pharmaceutical and MMS Holdings Collaborate to Gain FDA Approval to Begin Clinical Trials for the First Alzheimer’s Drug in 17 Years
5/5/2020
MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced that a successful collaboration with Shanghai-based Green Valley Pharmaceutical Co. (Green Valley) resulted in gaining U.S. Food & Drug Administration (FDA) approval of an Investigational New Drug (IND) application for the GV-971 international multi-center Phase 3 clinical study in the treatment of patients with Alzheimer’s disease.
-
MMS ANNOUNCES ONE MILLION DOLLAR AWARD FOR PHARMACEUTICAL COMPANIES DEVELOPING A VACCINE FOR COVID-19
3/20/2020
MMS Holdings (MMS) – an award-winning, data-focused CRO – announced today that it is offering a USD1M award toward the development of a vaccine for COVID-19, also known as the coronavirus.
-
A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.
-
MMS Holdings to Debut Datacise Integrated Safety Explorer to Detect Safety Signals Using Real-World Evidence During PHUSE/FDA Data Science Innovation Challenge
3/4/2020
MMS Holdings (MMS) – an award-winning, data-focused CRO – announced today that the Datacise Integrated Safety Explorer will make its debut at the 2020 PHUSE U.S. Connect conference in Orlando, Florida as part of the PHUSE/FDA Data Science Innovation Challenge, where, according to PHUSE, the “greatest minds in the data sciences arena come together and collaborate.”
-
MMS Holdings Doubles Growth in South Africa Region Amid Burgeoning Pharmaceutical Industry Locally
11/20/2019
MMS Holdings announced that its regional operations in South Africa has more than doubled in the past fiscal year, through the addition of new colleagues in Bloemfontein and the successful procurement of key contracts with clinical trial sponsors and research groups.
-
MMS Holdings Executive Michelle Gayari Joins Advisory Board of International Nonprofit That Provides Educational Programs to Children in Hospitals
10/23/2019
MMS Holdings announced that its Executive Director of Global Operations Michelle Gayari has joined the advisory board for the international 501 charity Together Educating All Children in Hospitals As its sole board member in the state of Michigan, Gayari will provide leadership, guidance, and fundraising support to help in bringing exciting, hands-on educational programs to children in hospitals.
-
MMS Holdings Announces Status as a Finalist for Best Contract Research Organization – Specialist Providers in Scrip Awards During 10th Annual Scientific Symposium
10/10/2019
CRO renews $250,000 commitment to volunteer program, kicks off leadership program
-
Oracle Health Sciences and MMS Collaborate to Deliver Complex Database Build for Oncology Sponsor
9/30/2019
MMS will share their learnings with peers at the Society for Clinical Data Management (SCDM) annual meeting in Baltimore, Md.
-
MMS Holdings Named Honorable Mention in Prestigious PR Daily Corporate Social Responsibility Awards for #OneMMS Volunteer Initiative
9/10/2019
MMS Holdings – an award-winning, data-focused CRO – was recently announced as an honorable mention recipient of PR Daily’s Corporate Social Responsibility Awards in the Engagement & Communications category for its #OneMMS volunteer campaign.
-
MMS Holdings and Sage IT Celebrate 10-Year Relationship with Deep Focus on Intelligent Automation and Bot Development
8/1/2019
Leveraging artificial intelligence (AI) and (NLP) for document development and authoring
-
Dr. Mike Poole Joins the Board of Scientific Advisors at Top Global CRO MMS Holdings
5/23/2019
The former Gates Foundation executive is helping redefine the CRO experience
-
Detroit-Area Life Sciences Firm Pledges More Than $250,000 in Employee Hours to Local Volunteer Initiatives
10/5/2018
MMS Holdings, Inc. (MMS) – award-winning, data-focused CRO – announced today its renewed dedication to the local communities surrounding Detroit and Ann Arbor by allocating a substantial amount of colleague time to volunteer initiatives over the next year.
-
MMS Supported Clinical Data Aspects in Gemphire Therapeutics Meeting its Primary Endpoint in Gemcabene Study
7/10/2018
MMS Holdings Inc. announced its integrated support for Gemphire Therapeutics Inc
-
MMS Hires CRO Leader Lisa James as Director of Business Operations and Client Relations
6/13/2018
MMS Holdings, Inc. (MMS) - a leading global clinical research organization - announced today that Lisa James has joined as Director, Business Operations and Client Relations.
-
MMS Promotes Two Leaders at its Asia Headquarters amid Strong Growth Period
6/7/2018
Is among the lowest attrition rates in the pharmaceutical industry regionally.
-
MMS Partners with University of Findlay to Provide Medical Writing and Clinical Trial Disclosure Courses
5/2/2018
The MMS Courses offered provide the necessary technical writing skills needed to be a successful medical writer preparing documents to support drug development and in preparing clinical trial disclosures.
-
MMS Selected by Paratek to Support its NDA Submissions for Omadacycline
11/16/2017
MMS announced today that it was selected by Paratek Pharma to support the development of its U.S. NDAs for omadacycline.